URL Pharma Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • URL Pharma's estimated annual revenue is currently $44.8M per year.(i)
  • URL Pharma's estimated revenue per employee is $201,000

Employee Data

  • URL Pharma has 223 Employees.(i)
  • URL Pharma grew their employee count by 1% last year.

URL Pharma's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M2156%N/AN/A
#2
$81.8M40710%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M2231%N/AN/A
#6
$13.1M655%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M86-5%N/AN/A
#9
$67.9M33823%N/AN/A
#10
$14.9M747%N/AN/A
Add Company

What Is URL Pharma?

URL Pharma is a leading specialty pharmaceutical company with fully integrated technology development, product development, manufacturing, and commercialization capabilities. We leveraged over 60 years of experience, as a generic pharmaceutical R&D and manufacturing company, to successfully transition into a growing, profitable, and technology driven proprietary branded pharmaceutical business.

keywords:N/A

N/A

Total Funding

223

Number of Employees

$44.8M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

URL Pharma News

2022-04-20 - North America Protein Expression Market Growth Sturdy at 9.0 ...

... the pharma industry can respond robustly to the health crisis but at a cost that ... Web URL: https://www.businessmarketinsights.com/.

2022-04-19 - We are bullish on pharma and manufacturing themes: Nilesh Shah

Nilesh Shah, MD, Kotak Mahindra AMC, in conversation with ET Now's Nikunj Dalmia at the Times Network India Economic Conclave during a panel...

2022-04-17 - North America Botulinum Toxin Market is expected to reach ...

... Merz Pharma, Medytox, Sanofi, Ipsen Pharma, Galderma, Revance Therapeutics Inc., ... Web URL: https://www.businessmarketinsights.com/.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$78.7M2232%N/A
#2
$67.1M2267%N/A
#3
$15M2286%N/A
#4
$15M2297%N/A
#5
$35.3M22925%N/A